SOURCE: Techs Loanstar, Inc.

Techs Loanstar, Inc.

April 12, 2012 08:00 ET

Quture/TCLN Announces Launch of International Initiatives for Its Healthcare Performance and Outcomes Product

Richard Fantozzi, M.D., Quture CEO, Participating on the Faculty of the Future Health Meeting of Europe, Africa & Americas in Lisbon, Portugal

PORT ORANGE, FL--(Marketwire - Apr 12, 2012) - Quture International, Inc. (OTCQB: TCLN) (PINKSHEETS: TCLN) and its operations subsidiary Quture, Inc. ("Quture") announce the beginning of their European and international campaigns for its QualOptima product at the Future Health Congress of Europe, Africa and the Americas beginning today in Lisbon, Portugal ( Richard Fantozzi, M.D., was invited as the CEO of Quture to participate as a panel member at the Congress by Carlos Thomas, President of the Board of Directors, APEGSAUDE ( with such dignitaries as Paulo Portis, Minister of Foreign Affairs, Portugal and a distinguished faculty of international health leaders. Dr. Fantozzi is focusing his remarks on two of the five themes of the conference: improving results and spreading innovation in healthcare internationally. He is accompanied by European representatives of InterSystems, a sponsor of the Congress (along with IBM and Hewlett-Packard of the United States) and in meetings with hospital customers of InterSystems in Portugal and Spain.

"We were persuaded by pressures from Europe to escalate our plans originally announced in the Super 8-K filing to become the international standard in healthcare performance and outcomes measurement," said Landon Feazell, Chairman & CEO of Quture International, Inc. "Performance analytics is truly the international solution to improve care and reduce costs. It is not just an American solution, it is the global solution. We believe our QualOptima product will be a major force in the transformation of healthcare payment and delivery systems."

The meeting is a part of the Portuguese Health Congress, on April 13 and 14 in Lisbon, Portugal ( Other conference themes focus on building bridges between people, putting resources together, cooperating for growth, and better health for all. InterSystems' products are already installed in over 100 hospitals in Portugal and Spain, and the Ensemble interface engine is the essential technology of the QualOptima product as a value-added license.

Richard Fantozzi, M.D., CEO and Co-Chairman of Quture, said: "I am excited to participate in the Congress along with other international healthcare leaders, such as Pedro Garcia of Chile, who was with me at the InterSystems Global Summit recently in Orlando." He added: "Quture is poised to commercially market our truly revolutionary product to enhance clinical performance and achieve optimal patient outcomes. The technology is capable of transforming both healthcare delivery and payment systems internationally."

Quture International, Inc. is an emerging growth company positioned to become the leading clinical knowledge company in the world. The core competence of Quture is clinical performance enhancement to achieve optimal patient outcomes. Quture's brand is centered on the value proposition of trust, transparency and independence. As the free enterprise solution to improving health and healthcare while reducing costs, Quture is comprised of a subsidiary for the operations of its software technology solutions, plans for a "beyond data" consulting and knowledge applications company, as well as plans for a personalized, proactive, and predictive medicine company with a virtual community of members. These subsidiaries will all be affiliated with the Qx Medical Exchange, which the Company intends to become the largest medical and health exchange in the world. Quture International is a Nevada corporation currently trading under the symbol TCLN.

Quture, Inc. ( is the operations subsidiary of Quture International, Inc., positioned to become the international standard in healthcare performance, outcomes and analytics. Quture's transformational product QualOptima operates on the InterSystems technology platform, the leading software platform globally for healthcare. QualOptima is the transcendent healthcare analytics system for performance enhancement to achieve optimal patient outcomes. The analytics system measures performance against evidence-based optimal clinical processes of care. The clinical data repository of QualOptima, the Qualytx integrated aggregate clinical database, is planned to become the international common data platform for health and healthcare. Qualytx will then be capable of transforming personal health and healthcare through knowledge solutions founded on Quture's proprietary science of knowing what to measure, where that data resides in disparate databases, using the InterSystems technology to electronically abstract that data, and converting data to knowledge and actionable insight with its revolutionary and proprietary analytics system. As America transitions to payment for value and U.S. and international pressures converge to measure performance, Quture will navigate the future of global health and healthcare quality, patient safety and value.

This release contains forward-looking statements, including, without limitation, statements concerning our business and possible or assumed future results of operations. Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons including: our ability to continue as a going concern, adverse economic changes affecting markets we serve; competition in our markets and industry segments; our timing and the profitability of entering new markets; greater than expected costs, customer acceptance of our products or difficulties related to our integration of the businesses we may acquire; and other risks and uncertainties as may be detailed from time to time in our public announcements and SEC filings. Although we believe the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and our future results, levels of activity, performance or achievements may not meet these expectations. We do not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in our expectations, except as required by law. There is no assurance that a definitive agreement will be completed.

Contact Information

  • For Further Information Contact:
    Constellation Asset Advisors, Inc.
    Jens Dalsgaard
    +1 (415) 524-8500

    Mele Telitz
    Director of Communications